eprintid: 10153042 rev_number: 7 eprint_status: archive userid: 699 dir: disk0/10/15/30/42 datestamp: 2022-08-02 10:15:14 lastmod: 2022-08-02 10:15:14 status_changed: 2022-08-02 10:15:14 type: article metadata_visibility: show sword_depositor: 699 creators_name: Moulinet, Ines creators_name: Touron, Edelweiss creators_name: Mezenge, Florence creators_name: Dautricourt, Sophie creators_name: de la Sayette, Vincent creators_name: Vivien, Denis creators_name: Marchant, Natalie L creators_name: Poisnel, Geraldine creators_name: Chetelat, Gael title: Depressive Symptoms Have Distinct Relationships With Neuroimaging Biomarkers Across the Alzheimer's Clinical Continuum ispublished: pub divisions: C07 divisions: FH5 divisions: B02 divisions: UCL divisions: D79 keywords: Science & Technology, Life Sciences & Biomedicine, Geriatrics & Gerontology, Neurosciences, Neurosciences & Neurology, Alzheimer's disease, amyloid deposition, cognition, depressive symptoms, anxiety, glucose metabolism, subjective cognitive decline, gray matter, MILD COGNITIVE IMPAIRMENT, POSITRON-EMISSION-TOMOGRAPHY, SUBJECTIVE MEMORY COMPLAINTS, CORTICAL AMYLOID DEPOSITION, QUALITY-OF-LIFE, NEUROPSYCHIATRIC SYMPTOMS, OLDER-ADULTS, MATTER HYPOMETABOLISM, PSYCHIATRIC-SYMPTOMS, BEHAVIORAL SYMPTOMS note: This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third-party material in this article are included in the Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ abstract: Background: Depressive and anxiety symptoms are frequent in Alzheimer’s disease and associated with increased risk of developing Alzheimer’s disease in older adults. We sought to examine their relationships to Alzheimer’s disease biomarkers across the preclinical and clinical stages of the disease. Method: Fifty-six healthy controls, 35 patients with subjective cognitive decline and 56 amyloid-positive cognitively impaired patients on the Alzheimer’s continuum completed depression and anxiety questionnaires, neuropsychological tests and neuroimaging assessments. We performed multiple regressions in each group separately to assess within group associations of depressive and anxiety symptoms with either cognition (global cognition and episodic memory) or neuroimaging data (gray matter volume, glucose metabolism and amyloid load). Results: Depressive symptoms, but not anxiety, were higher in patients with subjective cognitive decline and cognitively impaired patients on the Alzheimer’s continuum compared to healthy controls. Greater depressive symptoms were associated with higher amyloid load in subjective cognitive decline patients, while they were related to higher cognition and glucose metabolism, and to better awareness of cognitive difficulties, in cognitively impaired patients on the Alzheimer’s continuum. In contrast, anxiety symptoms were not associated with brain integrity in any group. Conclusion: These data show that more depressive symptoms are associated with greater Alzheimer’s disease biomarkers in subjective cognitive decline patients, while they reflect better cognitive deficit awareness in cognitively impaired patients on the Alzheimer’s continuum. Our findings highlight the relevance of assessing and treating depressive symptoms in the preclinical stages of Alzheimer’s disease. date: 2022-06-20 date_type: published publisher: FRONTIERS MEDIA SA official_url: https://doi.org/10.3389/fnagi.2022.899158 oa_status: green full_text_type: pub language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 1965226 doi: 10.3389/fnagi.2022.899158 medium: Electronic-eCollection lyricists_name: Marchant, Natalie lyricists_id: NLMAR24 actors_name: Marchant, Natalie actors_id: NLMAR24 actors_role: owner funding_acknowledgements: [Agence Nationale de la Recherche (LONGVIE, 2007) Association France Alzheimer et maladies apparentees AAP 2013]; [Fondation Plan Alzheimer (Alzheimer Plan 2008-2012)]; [Institut National de la Sante et de la Recherche Medicale (INSERM)]; 667696 [European Union's Horizon2020 Research and Innovation Program]; PHRCN 2011-A01493-38 [Programme Hospitalier de Recherche Clinique]; PHRCN 2012 12-006-0347 [Programme Hospitalier de Recherche Clinique]; [Region Basse-Normandie]; [French Ministere de l'Enseignement Superieur et de la Recherche]; [French ministerial scholarship and University grant for traveling and attending a scientific meeting in Berlin]; [Inserm]; [European Union Horizon 2020]; [Alzheimer's Society]; [European Union Horizon 2020 and Medical Research Council]; [European Union's Horizon 2020 research and innovation programme]; 667696 [EU's Horizon 2020 research and innovation programme]; [Fondation d'entreprise MMA des Entrepreneurs du Futur]; [Fondation Alzheimer]; [Programme Hospitalier de Recherche Clinique]; [Region Normandie]; [Association France Alzheimer et maladies apparentees]; [Fondation Vaincre Alzheimer] full_text_status: public publication: Frontiers in Aging Neuroscience volume: 14 article_number: 899158 pages: 12 event_location: Switzerland citation: Moulinet, Ines; Touron, Edelweiss; Mezenge, Florence; Dautricourt, Sophie; de la Sayette, Vincent; Vivien, Denis; Marchant, Natalie L; ... Chetelat, Gael; + view all <#> Moulinet, Ines; Touron, Edelweiss; Mezenge, Florence; Dautricourt, Sophie; de la Sayette, Vincent; Vivien, Denis; Marchant, Natalie L; Poisnel, Geraldine; Chetelat, Gael; - view fewer <#> (2022) Depressive Symptoms Have Distinct Relationships With Neuroimaging Biomarkers Across the Alzheimer's Clinical Continuum. Frontiers in Aging Neuroscience , 14 , Article 899158. 10.3389/fnagi.2022.899158 <https://doi.org/10.3389/fnagi.2022.899158>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10153042/1/Depressive%20Symptoms%20Have%20Distinct%20Relationships%20With%20Neuroimaging%20Biomarkers%20Across%20the%20Alzheimers%20Clinical%20Continuum.pdf